Indolent B-Cell Lymphoma
The latest news, research, and perspectives in indolent B-cell lymphoma. This diverse group of slow-growing non-Hodgkin lymphomas form in B cells and include follicular lymphoma, hairy cell leukemia, and marginal zone lymphoma.
Advertisement
The ELM-2 trial studied odronextamab in patients with relapsed or refractory follicular lymphoma.
Common adverse reactions to zanubrutinib observed across studies included decreased neutrophil and platelet counts.
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Real-world treatment outcomes with bendamustine in indolent B-cell non-Hodgkin lymphoma were similar to those in trial data.
Patients with LBCL who received CAR T-cell therapy earlier in treatment had lower occurrences of severe neutropenia.
At a median follow-up of 18.1 months, the ORR and CR rates were both 95.7% following liso-cel treatment.
Advertisement
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
Cancer Research & Treatment Fund (CR&T) invests in research related to the prevention and treatment of blood cancers.
The trial studied a fixed-duration regimen of mosunetuzumab plus lenalidomide in follicular lymphoma.
Among 26 response-evaluable patients, the best overall response rate was 96% and the complete response rate was 81%.
Lenalidomide, rituximab, and ibrutinib was effective as a first-line therapy for patients with follicular lymphoma and MZL.
Around two-thirds of patients with follicular lymphoma receive at least two lines of therapy during their lifetime.
Orelabrutinib induced high response rates and sustained remission in relapsed or refractory marginal zone lymphoma,
It included 21 patients with lymphoma with a median age of 57 who had received a median of four prior lines of therapy.
Researchers reviewed data on gender, race/ethnicity, zip codes to estimate poverty level, and other factors.
Dr. Dickinson joins "Blood Cancer Talks" hosts to discuss phase I and II trials on DLBCL, follicular lymphoma, and more.
Researchers assessed the number of patients who received subsequent treatment after tirabrutinib discontinuation.
The findings "may contribute to future improved risk assessment and personalized management strategies for patients."
Researchers used a classification approach derived from machine learning to stratify patients into two subgroups.
The combination was previously “found to be well tolerated with an early signal of efficacy in a phase Ib study.”
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.